The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year injectable drug to be used for HIV ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

And other biotech news brought to you by The Readout.

How an Indian contract manufacturer will establish a biotech foothold in the U.S.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Lenacapavir is an antiretroviral medicine that helps prevent 99.9 per cent of all HIV transmission, according to studies.